Report on the risk assessment of 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe) in the framework of the Council Decision on new psychoactive substances


SThis report presents the data and findings of the risk assessment on the new psychoactive substance, 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe), that was conducted by the Scientific Committee of the EMCDDA. Concerns over this hallucinogenic drug in the European Union led to an assessment of the health and social risks posed by the substance in April 2014.

Download as PDF

Table of contents

  • EMCDDA actions on monitoring and responding to new drugs
  • EMCDDA–Europol Joint Report on 25I-NBOMe: a summary
  • Risk Assessment Report of a new psychoactive substance: 25I-NBOMe
  • Annex 1: Technical report on 25I-NBOMe
  • Council Implementing Decision of 25 September 2014 on subjecting 25I-NBOMe, AH-7921, MDPV and methoxetamine to control measures
  • Participants of the risk assessment meeting

Additional downloads